Phathom Pharmaceuticals, Inc. PHAT

US Pharmaceuticals

$5.40 ▲ +1.31% (+$0.07)

Open $5.22

Prev Close $5.33

Day Range $5.22 – $5.56

52W Range $5.02 – $18.31

Market Cap $433.28M

Beta 0.60

EPS (TTM) $-1.03

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-10-25
Shares Out.	81,290,000
Website	phathompharma.com/ ↗
Phone	13026365400
Employees	371
Revenue	$84.7M
Gross Profit	$66.4M
Net Income	-$13.9M
Free Cash Flow	-$21.0M
Total Assets	$345.0M
Total Liabilities	$692.7M
Equity	-$347.6M

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Phathom Pharmaceuticals, Inc. is a publicly traded company under the ticker symbol PHAT on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.